There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Benitec Biopharma (BNTC – Research Report), Bluebird Bio (BLUE – Research Report) and AC Immune SA (ACIU – Research Report) with bullish sentiments.
Benitec Biopharma (BNTC)
In a report issued on November 14, Mani Foroohar from Leerink Partners maintained a Buy rating on Benitec Biopharma, with a price target of $20.00. The company’s shares closed last Monday at $9.58.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of
Benitec Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $24.00, implying a 125.4% upside from current levels. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bluebird Bio (BLUE)
Robert W. Baird analyst Jack Allen maintained a Buy rating on Bluebird Bio on November 14 and set a price target of $6.00. The company’s shares closed last Monday at $0.33, close to its 52-week low of $0.32.
According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of
Bluebird Bio has an analyst consensus of Hold, with a price target consensus of $2.30, representing a 609.7% upside. In a report issued on November 15, Barclays also maintained a Buy rating on the stock with a $2.00 price target.
AC Immune SA (ACIU)
Leerink Partners analyst Marc Goodman maintained a Buy rating on AC Immune SA on November 14. The company’s shares closed last Monday at $3.14.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AC Immune SA with a $12.00 average price target, a 275.0% upside from current levels. In a report issued on November 17, BTIG also maintained a Buy rating on the stock with a $8.00 price target.
Read More on BNTC:
- Benitec Biopharma Awards Bonuses to Key Executives
- BNTC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Benitec Biopharma files $125M mixed securities shelf
- Benitec Biopharma initiated with an Outperform at Oppenheimer
- Benitec Biopharma participates in a conference call with Piper Sandler
